Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Poland

Research and Innovation Action · Running

SECURE Strengthening the European Chain of sUpply for next generation medical RadionuclidEs

Coordinator
Narodowe Centrum Badan Jadrowych, Poland
Runs
1 October 2022 to 30 September 2025
Status
Running
EU funding
€3.6m
Total cost
€3.7m
Partners
18 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101061230

What the project is doing

In the project's own words, from its summary on CORDIS.

SECURE project aims to make a major contribution to the sustainability of medical isotope production and its safe application in Europe. It is focusing on promising developments in the design of irradiation targets, production routes for existing and new isotopes in nuclear therapy and diagnostics. Isotopes critical in the success of nuclear medicine are selected and research activities are identified to address some of the major challenges in securing its future availability, with the objectives:1.to remove critical barriers along the production of its selected alpha and beta emitting isotopes that restrict a sustainable production, 2.to develop a framework of guidance and recommendations that enables exploring the full clinical potential of alpha and beta particle therapy and its safe application 3.to provide important lessons learned that act as a demonstration case for addressing issues in upscaling and sustained isotope production.

At present, Ra-223 is the only radiopharmaceutical which has been granted marketing authorization to treat adults with prostate cancer. This has paved the way for a wider use of other alpha emitters such as Ac-225 or Bi-213. The expected demand of nuclear medicine for novel alpha emitters and beta- emitters requires re-evaluation of their production methods and inventories of target materials and parent radionuclides.

The ambition of SECURE consortium is to identify and efficiently use the current resources for new radionuclides, in particular for alpha emitters and the relevant beta emitting theranostic radionuclides. The development of alternative technologies for production of such therapeutic radionuclides for improved patient treatment requires multidisciplinary scientific and technological knowledge including physics, chemistry, material science, machining of target materials, chemistry, biology and radiobiology, radiopharmacy and nuclear medicine.

All this chain of expertise is present in SECURE consortium.

Topics

Who is involved

OrganisationCityCountryRole
Narodowe Centrum Badan JadrowychOtwockPolandCoordinator
European Nuclear Education NetworkBruxelles / BrusselBelgiumParticipant
Jrc -Joint Research Centre- European CommissionBruxelles / BrusselBelgiumParticipant
Studiecentrum Voor Kernenergie / Centre D'etude De L'energie NucleaireBruxelles / BrusselBelgiumParticipant
Evalion SroPrahaCzechiaParticipant
Institut Max Von Laue - Paul LangevinGrenobleFranceParticipant
Universite De BrestBrestFranceParticipant
Budapesti Muszaki Es Gazdasagtudomanyi EgyetemBudapestHungaryParticipant
Hun-Ren Energiatudomanyi KutatokozpontBudapestHungaryParticipant
Agenzia Nazionale per Le Nuove Tecnologie, L'energia E Lo Sviluppo Economico SostenibileRomaItalyParticipant
Clust-Er Industrie Della Salute E Del BenessereBolognaItalyParticipant
Istituto Romagnolo per Lo Studio Dei Tumori Dino Amadori - Irst SRLMeldolaItalyParticipant
European Federation of Organisations for Medical PhysicsUtrechtNetherlandsParticipant
Nrg Pallas BVPettenNetherlandsParticipant
Clusterul Regional Inovativ De Imagistica Moleculara Si Structurala Nord-Est (imago-Mol)IasiRomaniaParticipant
Institut Jozef StefanLjubljanaSloveniaParticipant
Univerzitetni Klinicni Center LjubljanaLjubljanaSloveniaParticipant
United Kingdom National Nuclear Laboratory LimitedWarringtonUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS